Andras A. Heczey, MD

Location

  • Texas Medical Center

Specialty

Cancer

Phone: 832-822-4242
Fax: 832-825-1453

Contact Information

1102 Bates Ave.
Suite 1760.10
Houston, TX 77030
United States
Texas

Research Area

  • Liver Tumors
  • Neuroblastoma

Director, Liver Tumor Program
Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine

Education

School Education Degree Year
Baylor College of Medicine fellowship Pediatric Hematology Oncology 2012
Children's Hospital of Los Angeles residency Pediatrics 2009
Semmelweis Medical University, Hungary residency Infectious Disease 2006
Semmelweis University medical school Doctor of Medicine 2002

About

Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology/Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT).

Board Certifications
General Pediatrics, American Board of Pediatrics
Pediatric Hematology and Oncology, American Board of Pediatrics

News Articles

New Approach for Liver Cancer 

Organization

Organization Name Role
American Society of Cell and Gene Therapy (ASCGT) Member
American Society of Clinical Oncology (ASCO) Member
American Society of Pediatric Hematology and Oncology (ASPHO) Member
Children's Oncology Group (COG) Member

Research Statement

Dr. Andras Heczey's research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack and kill cancer cells by using genetically-engineered T cells and Natural Killer T cells.

As the Director of the Liver Tumor Center, Dr. Heczey developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically-engineered T lymphocytes. He is currently optimizing this strategy for a smooth transition into the clinic. He developed bispecific T cell engagers and chimeric antigen receptors which specifically target hepatoblastoma and hepatocellular carcinoma when expressed in T cells. His goal is to cure all patients with liver cancers by translating these methods from the laboratory setting to the patient care clinic.

In regards to neuroblastoma, Dr. Heczey studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells (NKT cells) that are genetically-modified to attack neuroblastoma. He aims to transition this approach from bench-to-bedside as a Phase 1/2a clinical trial.

Awards

2000              Good Student and Good Athlete of the Republic of Hungary, Ministry of Education of Hungary

2009              Associates and Affiliates Award of the Children's Hospital of Los Angeles, for scientific knowledge, clinical judgment and excellence in human relations

2010              Tumor Board Award, Texas Children's Cancer and Hematology Centers

2011-2012     Chief Fellow, Texas Children's Cancer and Hematology Centers

2015              Fellows’ Excellence in Education Award, Texas Children's Cancer and Hematology Centers

2017              Faculty Recognition Award, Texas Children’s Cancer and Hematology Centers 

2017              Biotherapeutics Award, Alex's Lemonade Stand Foundation 

Related Videos

  • Embedded thumbnail for TARE procedure available for pediatric liver cancer patients at Texas Children's Hospital
    TARE procedure available for pediatric liver cancer patients at Texas Children's Hospital
  • Embedded thumbnail for Liver Tumor Program at Texas Children's Cancer Center
    Liver Tumor Program at Texas Children's Cancer Center